137 Andersen $L Lauberg P:Antithy. IClin Endocrin Metab 01 138 ther en PR:High dose of 148 206155783 mMctb2802871073-107 Cn Endo- 149 ntith s'dis 150 140 Nakamura H,Noh JY,Itoh K.Fukata,Mi- pcainthro medication use,and 仁a d An cd5nsL,olsen 153 Alexander KPaeENeGA wn cters RP. and 1.2 163 sefollowingim ctors of outcome 155 Pearce SH:Spo g of ad fere 1201480-629-69 164 Smith 1589 1468358 156 of endo ociated ophthalmopa 186 8hm0sa6-16 Kahaly/Bartalena/Hegedus/Leenhardt/ Poppe/Pearce 医通 http://guide.medlive.cn/ Kahaly/Bartalena/Hegedüs/Leenhardt/ Poppe/Pearce 186 Eur Thyroid J 2018;7:167–186 DOI: 10.1159/000490384 137 Andersen SL, Olsen J, Laurberg P: Antithy￾roid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab 2016; 101:1606–1614. 138 Alexander EK, Larsen PR: High dose of 131I therapy for the treatment of hyperthyroid￾ism caused by Graves’ disease. J Clin Endo￾crinol Metab 2002;87:1073–1077. 139 Nicholas WC, Fischer RG, Stevenson RA, Bass JD: Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995;88:973–976. 140 Nakamura H, Noh JY, Itoh K, Fukata S, Mi￾yauchi A, Hamada N: Comparison of me￾thimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2007;92: 2157–2162. 141 Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA: Prevalence of thyrotoxi￾cosis, antithyroid medication use, and com￾plications among pregnant women in the United States. Thyroid 2013;23:758–765. 142 Andersen SL, Olsen J, Wu CS, Laurberg P: Birth defects after early pregnancy use of an￾tithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013;98:4373– 4381. 143 Rubin PC: Current concepts: beta-blockers in pregnancy. N Engl J Med 1981;305:1323– 1326. 144 Momotani N, Hisaoka T, Noh J, Ishikawa N, Ito K: Effects of iodine on thyroid status of fetus versus mother in treatment of Graves’ disease complicated by pregnancy. J Clin Endocrinol Metab 1992;75:738–744. 145 Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S: Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 2002;147: 583–589. 146 Laurberg P, Andersen SL: Therapy of endo￾crine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur J Endo￾crinol 2014;171:R13–R20. 147 Laurberg P: Remission of Graves’ disease during anti-thyroid drug therapy: time to re￾consider the mechanism? Eur J Endocrinol 2006;155:783–786. 148 Bliddal S, Rasmussen AK, Sundberg K, Brocks V, Feldt-Rasmussen U: Antithyroid drug-induced fetal goitrous hypothyroid￾ism. Nat Rev Endocrinol 2011;7:396–406. 149 McKenzie JM, Zakarija M: Fetal and neona￾tal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992;2:155–159. 150 Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C: Predictive value of maternal second-generation thyroid-binding inhibi￾tory immunoglobulin assay for neonatal au￾toimmune hyperthyroidism. Eur J Endocri￾nol 2014;171:451–460. 151 Cove DH, Johnston P: Fetal hyperthyroid￾ism: experience of treatment in four siblings. Lancet 1985;1:430–432. 152 Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, Kurachi K, Kumahara Y, Miyai K: Aggravation of thyrotoxicosis in early preg￾nancy and after delivery in Graves’ disease. J Clin Endocrinol Metab 1982;55:108–112. 153 Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laur￾berg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S: 2017 guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017;27:315–389. 154 Mandel SJ, Cooper DS: The use of antithy￾roid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001;86:2354–2359. 155 Pearce SH: Spontaneous reporting of ad￾verse reactions to carbimazole and propyl￾thiouracil in the UK. Clin Endocrinol 2004; 61:589–594. 156 Perros P, Crombie AL, Matthews JN, Kend￾all-Taylor P: Age and gender influence the severity of thyroid-associated ophthalmopa￾thy: a study of 101 patients attending a com￾bined thyroid-eye clinic. Clin Endocrinol 1993;38:367–372. 157 Leger J, Gelwane G, Kaguelidou F, Ben￾merad M, Alberti C; French Childhood Graves’ Disease Study Group: Positive im￾pact of long-term antithyroid drug treat￾ment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab 2012;97: 110–119. 158 Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Su￾zuki M, Yoshihara A, Ito K, Ito K: Antithy￾roid drug treatment for graves’ disease in children: a long-term retrospective study at a single institution. Thyroid 2014;24:200– 207. 159 Rivkees SA, Szarfman A: Dissimilar hepato￾toxicity profiles of propylthiouracil and me￾thimazole in children. J Clin Endocrinol Metab 2010;95:3260–3267. 160 Ma C, Kuang A, Xie J, Liu G: Radioiodine treatment for pediatric Graves’ disease. Co￾chrane Database Syst Rev 2008;3:CD006294. 161 Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691–1695. 162 Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP: Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with ad￾vanced human immunodeficiency virus (HIV) disease. Medicine 2005;84:98–106. 163 Weetman AP: Graves’ disease following im￾mune reconstitution or immunomodulato￾ry treatment: should we manage it any dif￾ferently? Clin Endocrinol 2014;80:629–632. 164 Furmaniak J, Sanders J, Nunez Miguel R, Rees Smith B: Mechanisms of action of TSHR autoantibodies. Horm Metab Res 2015;47:735–752. 165 Gershengorn MC, Neumann S: Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 2012;97:4287–4292. 166 El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L: The rationale for B lymphocyte depletion in Graves’ disease: monoclo￾nal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006; 154:623–632. http://guide.medlive.cn/